Evaluation of Ultralow Dose PET Imaging for Detecting 18F-FDG Uptake
Akiva Mintz
Summary
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDG and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours.
Description
This research study aims to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. "Investigational" means that the procedure or drug being studied is not yet approved by the FDA for the specific use being tested in this research. The PET imaging technique used in this study is considered investigational because it is being tested at an ultralow radiation dose that has not yet been approved for clinical use. The radiotracer, 18F-FDG, is FDA-approved for detecting cancer at standard doses. 18F-FDG is often found to be taken up at higher levels in c…
Eligibility
- Age range
- 18–120 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: 1. Age ≥18 years. 2. Ability to provide informed consent and comply with study procedures. 3. For female participants: * Must not be pregnant or breastfeeding. * Negative pregnancy test required for women of childbearing potential. Exclusion Criteria: 1. Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total). 2. More than four prior enrollments in this study. 3. Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of t…
Interventions
- Drug18F-FDG
Participants will be injected with 18F-FDG and imaged for up to 3 hours on a PET scanner
Location
- Nuclear Imaging InstituteEnglewood, New Jersey